valcyte效果好吗？

Is it effective to treat CMV retinitis? Valcyte is the prodrug of ganciclovir and an active valine ester of ganciclovir. After oral administration, it can be rapidly hydrolyzed into ganciclovir by phosphatase in intestinal and liver cells. Its antiviral spectrum and mechanism of action are similar to ganciclovir, but its bioavailability is significantly higher than that of ganciclovir. Its oral bioavailability is 62.4%, which is 10 times that of ganciclovir, while its toxicity is greatly reduced.

Adult patients should use valcyte tablets rather than valcyte oral solution. Oral solutions and tablets should be taken with food. Valcyte tablets should not be cracked or crushed. Before dispensing the medication to a patient, the pharmacist must prepare an oral solution (50 mg/ml) with valcyte.

Treatment of induction of cytomegalovirus retinitis: The recommended dose of valcyte is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.

The U.S. Food and Drug Administration (FDA) approves the increased use of valcyte in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylactic treatment with valcyte reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients who received 100 days of treatment) to 16.8% (for patients who received 200 days of treatment one year after receiving a kidney transplant) (p <0.0001).1.2 The overall safety profile of valcyte did not change when prophylaxis was extended in high-risk renal transplant patients.

The antiviral effect of valcyte tablets has been clinically demonstrated in the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). After 4 weeks of tablet treatment, the detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55).